CA-VEEVA-SYSTEMS-INC.
16.9.2020 13:05:07 CEST | Business Wire | Press release
Accelerating clinical research is a top priority across sites, sponsors, and CROs. To help speed research, more sites are using Veeva SiteVault Free for managing study documentation and collaborating remotely with study monitors. In eight months since the product has been available from Veeva Systems (NYSE: VEEV), the number of SiteVault Free customers has increased to more than 500 in over 30 countries, signaling a rapid shift among global research sites to simplify and streamline study execution.
“Sites see a tremendous opportunity to reduce the time and effort in managing regulatory binders and improve how they share study information with sponsors,” said Bree Burks, RN, MSN, vice president of site strategy at Veeva and a former clinical research director. “We’re proud to support research sites around the world, making study execution and compliance easier so they can focus on important research and patient care.”
Veeva SiteVault eliminates manual and paper-based processes with a modern application to manage regulatory and source documentation compliant with 21 CFR Part 11 and HIPAA requirements. Capabilities such as electronic signatures, certified copy workflows, and reporting simplify compliance. With remote monitoring, sites can give study monitors secure and direct access to study binders from any location and streamline collaboration throughout every stage of source document review and verification.
Veeva SiteVault Free can be used for all trials regardless of what technology sponsors are using, as well as the site file for investigator-initiated trials. The application is free for clinical research sites and comes with full training and support.
For more information or to sign-up for SiteVault Free, visit sites.veeva.com . To learn more about remote monitoring, see a demo at sites.veeva.com/RemoteMonitoring .
What Sites are Saying About Veeva SiteVault Free
“We are reducing study activation timelines by 40%, spending half the time completing regulatory tasks, and saving tens of thousands of dollars per study with Veeva SiteVault Free,” said Justin Deck, chief clinical officer at Tilda Research. “Veeva has helped us dramatically improve the speed and efficiency of study execution for more than 50 studies across 18 different sponsors.”
“Our 4-hour in-person monitoring visits are now just 30 minutes using remote monitoring in Veeva SiteVault Free,” said Charles Sydnor, project manager at Crofoot Research Center. “The simplicity of the application makes it easy to collaborate remotely with study monitors. There’s also less administrative burden to maintain compliance, allowing our team to spend more time on patient care.”
“COVID-19 halted onsite visits just as we were in the process of locking our study database,” said Hanna Voltattorni, senior project manager at CNS, the largest clinical research provider in southern California. “Veeva allowed us to continue working with study monitors and keep the trial going. We are now using Veeva SiteVault Free across all our studies.”
“Veeva’s support and site-centric approach has streamlined our study processes and made operations much more efficient,” said Megan Ford, executive director, clinical trials at the Ingham Institute for Applied Medical Research. “We have now standardized on Veeva SiteVault Free across our research departments in all hospitals to simplify and streamline research.”
About Veeva SiteVault
Veeva SiteVault reduces the administrative burden of managing regulatory and source documents across all trials with capabilities such as remote monitoring, electronic signatures, certified copy workflows, and reporting. Available in two editions, SiteVault Free comes with full training and support, and SiteVault Enterprise provides customized reports, tailored workflows, and open APIs for integrations. For more information about Veeva SiteVault or to sign-up for SiteVault Free, visit sites.veeva.com
.
Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu
.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov
. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005463/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
Credit Derivatives Determinations Committees Membership applications for 202627.3.2026 17:30:00 CET | Press release
DC Administration Services, Inc. (DCAS) would like to invite all interested Members of ISDA to apply for a position as a member of the Credit Derivatives Determinations Committees. There is a separate Determinations Committee for each of the relevant regions. Members of ISDA may apply for membership as either a Dealer Member of the Determinations Committees or a Non-Dealer Member of the Determinations Committees (as applicable). Parties wishing to apply for such a position should carefully review and submit either an executed Dealer Participation Letter (for a prospective Dealer Member) or an executed Non-dealer Committee Participation Letter (for a prospective Non-Dealer Member) by 5pm (New York time) on Friday, April 3, 2026. CCPs may also apply to participate as a CCP Member by submitting a Participating CCP Institution Letter. For more information on the process and to download the form of the relevant letter, please visit https://www.cdsdeterminationscommittees.org/about-dc-commit
Andersen Consulting indgår samarbejdsaftale med Solutia27.3.2026 15:22:00 CET | Pressemeddelelse
Andersen Consulting udvider sin tilstedeværelse i Spanien gennem en samarbejdsaftale med Solutia, en virksomhed med speciale i løsninger inden for arbejdsmiljø og sundhed samt rekruttering inden for life science- og sundhedssektoren. Solutia blev stiftet i 2014 og tilbyder omfattende tjenester og rådgivning med fokus på sunde arbejdsmiljøer, sygefravær, outsourcing af sundhedsydelser og uddannelse til organisationer på tværs af alle sektorer. Virksomheden leverer også rekrutterings- og executive search-løsninger med fokus på life science, tekniske fagfolk samt mellem- og topledelse samt dybdegående ekspertise inden for medicinal-, bioteknologi-, medico- og sundhedsindustrien. Ved hjælp af datadrevne og skræddersyede løsninger hjælper Solutia virksomheder med at optimere medarbejdereffektiviteten og tiltrække specialister. "Vores mål er at forbedre, hvordan organisationer tiltrækker, udvikler og leder medarbejdere i et stadig mere komplekst miljø," udtalte Cesar Castel, administrerende
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom